Navigation Links
Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG
Date:12/9/2008

Phase 2 Results for Low-dose, Weekly Contraceptive Patch to be Presented at ACOG Meeting in May 2009

PRINCETON, N.J., Dec. 9 /PRNewswire/ --Agile Therapeutics, Inc., a late-stage pharmaceutical company specializing in women's health products, today announced that two abstracts from Phase 2 studies of its lead product, AG200-15 with SKINFUSION(TM) technology, were accepted by the American College of Obstetricians and Gynecologists Annual Clinical Meeting and will be presented in May 2009 at ACOG's annual meeting in Chicago.

AG200-15, a new, innovative, low-dose, weekly contraceptive patch entering Phase 3 clinical trials, represents a significant advancement in the women's healthcare market. As a convenient alternative to oral contraceptives, the patch will fill an unmet need, freeing women from having to remember to take a pill every day. Phase 2 clinical study results will be presented on safety, efficacy and dosage for AG200-15, in which the product met its primary endpoints of ovulation suppression, cycle control and safety and demonstrated estrogen levels comparable with the well-established, low-dose oral contraceptive, Levlen(R).

Thomas Rossi, Ph.D., President and Chief Executive Officer of Agile Therapeutics, Inc., said, "This news represents another major milestone for AG200-15 with our patented SKINFUSION(TM) technology. Having two abstracts accepted for presentation at the premier obstetric-gynecology conference in the country reinforces the importance that this product will have for women as a contraceptive option."

The two abstracts scheduled for poster presentation are: (1) Pharmacokinetics: Contraceptive Patches Containing Levonorgestrel and Ethinyl Estradiol vs. Levlen(R), authored by David F. Archer, M.D., Frank Stanczyk, Ph.D., Arkady Rubin, Ph.D., and Marie Foegh, M.D., DrSc and will be presented on Monday, May 4, and (2) Ovulation Suppression and Cycle Control of Ethinyl Estradiol and Levonorgestrel Combination Patches, authored by Daniel R. Mishell Jr., M.D., David F. Archer, M.D., Arkady Rubin, Ph.D., Marie Foegh, M.D., DrSc, to be presented on Tuesday, May 5.

Marie Foegh, M.D., DrSc, Vice President, Clinical Research and Development at Agile Therapeutics, Inc., commented, "We are very excited to be working closely with leaders in the field of women's reproductive health, including David Archer M.D., Daniel Mishell M.D., and Frank Stancyk Ph.D., and to share positive safety and efficacy data on this important new entry into the contraceptive market."

Daily oral contraceptives and condoms are currently the most popular methods of birth control. In a 500 patient survey, sponsored by Agile, a weekly contraceptive patch was preferred over the pill by a 4-to-1 margin by women desiring contraception. Interest in an alternative to the daily birth control pill was also seen in another Agile-sponsored survey of 1,000 women using or desiring contraception. In that study, more than half of the women surveyed said they would ask their doctor about AG200-15, a low-dose, weekly contraceptive patch, after reading its profile.

About AG200-15, Agile's Low-Dose Contraceptive Patch

AG200-15 with SKINFUSION(TM) technology is a low-dose, weekly contraceptive patch that is entering Phase 3 development with a clearly defined regulatory pathway. SKINFUSION(TM) technology makes it possible to utilize the trusted hormone combination of levonorgestrel and ethinyl estradiol in a contraceptive patch. The patch was designed for flexibility and comfort.

About Estrogen

Estrogen is associated with certain side effects, such as breast tenderness, bloating/weight gain, nausea and vomiting. These side effects are believed to be related to the amount of hormones delivered into the bloodstream, particularly with higher levels of estrogen. In some rare cases, high estrogen levels are thought to be linked with serious cardiovascular side effects. Therefore, low doses of estrogen in hormonal contraception are desired. According to FDA product labeling, women using Ortho EVRA(R), the only marketed birth control patch, are exposed to about 60 percent more estrogen than if they were using typical low-dose birth control pills. Increased levels of estrogen may increase the risk of blood clots, which led the FDA to add warnings to Ortho EVRA's labeling.

About Agile Therapeutics, Inc.

Agile Therapeutics is a high-growth, late-stage pharmaceutical company specializing in women's health products prescribed by OB/GYNs with an initial focus on developing safer, more convenient methods of hormonal contraception. AG200-15, an innovative, weekly, low-dose contraceptive patch has the potential to become a major product in the $5 billion global hormonal contraceptive market (U.S. market $3 billion). AG200-15 is based on Agile's patented, dual delivery system, SKINFUSION(TM) technology, and utilizes the trusted hormonal combination of levonorgestrel and ethinyl estradiol.

The lead product is moving into Phase 3, with a clearly defined regulatory path. Agile is privately financed, with a solid foundation for growth. The Company has raised a total of $35 million in venture funding with experienced and committed healthcare investors, including ProQuest Investments, The Hillman Company, TL Ventures, and Novitas Capital. For more information, please visit http://www.agiletherapeutics.com.

LEVLEN(R)is a registered trademark of Berlex Laboratories

Ortho EVRA(R)is a registered trademark of OrthoMcNeil(TM)


'/>"/>
SOURCE Agile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. $21.8 Million NIH Grant for Fragile X Research
2. Stem cell research produces a key discovery for Fragile X Syndrome
3. Brain Defect Helps Drive Fragile X Syndrome
4. Fragile X Foundations Sign Merger Agreement
5. Fragile X Syndrome Corrected in Mice
6. Drosophila drug screen for fragile X syndrome finds promising compounds and potential drug targets
7. Prime Therapeutics Receives TIPPS Certification
8. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
9. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
10. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
11. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology: